KPTI

+ Watchlist + Portfolio

Karyopharm Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.00
52-Week Range: $1.79 – $10.99
Market Cap: $41.28M
P/E (TTM): —
EPS (TTM): -14.33
Dividend Yield: —

Advanced Metrics

Price/Book: —
PEG Ratio: —
Return on Equity: —
Return on Assets: -47.61%
Gross Margin: 13.39%
Operating Margin: -67.38%
Profit Margin: -153.28%
Current Ratio: 0.79
Debt/Equity: —
Total Debt: $328.53M
Free Cash Flow: $-29.67M
Revenue Growth: -11.90%
Earnings Growth: —
Enterprise Value: $308.79M

KPTI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$157.07M	$146.03M	$145.24M	$146.07M
Cost of Revenue	$5.21M	$4.94M	$6.01M	$5.95M
Gross Profit	$151.86M	$141.09M	$139.23M	$140.12M
Research & Development	$148.66M	$138.75M	$143.23M	$125.62M
Selling, General & Admin	$145.40M	$131.88M	$115.44M	$105.21M
Operating Expenses	$294.06M	$270.63M	$258.67M	$230.82M
Operating Income	-$142.20M	-$129.54M	-$119.44M	-$90.71M
EBITDA	-$139.31M	-$118.42M	-$38.60M	-$149.85M
Pretax Income	-$164.92M	-$142.78M	-$76.36M	-$196.00M
Income Tax	$369.00K	$323.00K	$57.00K	$43.00K
Net Income	-$165.29M	-$143.10M	-$76.42M	-$196.04M
Diluted EPS	-30.30	-18.79	-13.95	-17.93
Diluted Shares	5.46M	7.62M	8.45M	10.94M

KPTI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$135.19M	$52.23M	$62.48M	$60.54M
Receivables	$47.09M	$26.96M	$30.77M	$26.18M
Inventory	$4.22M	$3.04M	$4.74M	$4.04M
Current Assets	$350.16M	$233.92M	$156.46M	$103.15M
Total Assets	$358.17M	$240.44M	$164.42M	$108.42M
Current Liabilities	$65.91M	$69.48M	$92.26M	$92.06M
Long-Term Debt	$170.10M	$170.92M	$162.95M	$205.88M
Total Debt	$179.07M	$177.02M	$194.52M	$233.61M
Total Liabilities	$374.83M	$376.64M	$350.44M	$401.34M
Retained Earnings	-$1.34B	-$1.49B	-$1.56B	-$1.76B
Shareholders' Equity	-$16.66M	-$136.21M	-$186.02M	-$292.93M
Working Capital	$284.25M	$164.44M	$64.20M	$11.09M
Net Debt	$34.92M	$118.69M	$124.90M	$166.35M

KPTI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$149.55M	-$92.72M	-$127.49M	-$75.37M
Capital Expenditure	-$118.00K	—	-$142.00K	—
Free Cash Flow	-$149.67M	-$92.72M	-$127.63M	-$75.37M
Depreciation & Amortisation	$621.00K	$530.00K	$340.00K	$296.00K
Stock-Based Compensation	$35.40M	$21.71M	$18.43M	$14.05M
Investing Cash Flow	-$104.26M	$7.94M	$95.47M	$43.38M
Financing Cash Flow	$193.74M	$1.12M	$41.65M	$30.05M
Net Change in Cash	-$60.07M	-$83.66M	$9.63M	-$1.94M

KPTI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$30.02M	$37.93M	$44.04M	$34.08M	$35.07M
Cost of Revenue	$1.30M	$1.05M	$2.11M	$1.48M	$1.34M
Gross Profit	$28.71M	$36.88M	$41.93M	$32.59M	$33.72M
Research & Development	$34.62M	$32.79M	$30.54M	$27.67M	$33.80M
Selling, General & Admin	$27.35M	$28.48M	$26.61M	$22.77M	$26.68M
Operating Expenses	$61.97M	$61.27M	$57.15M	$50.44M	$60.48M
Operating Income	-$33.26M	-$24.39M	-$15.22M	-$17.84M	-$26.76M
EBITDA	-$12.35M	-$25.91M	-$21.96M	-$89.63M	-$9.83M
Pretax Income	-$23.43M	-$37.21M	-$33.09M	-$102.27M	-$22.39M
Income Tax	$36.00K	$40.00K	$34.00K	-$67.00K	$1.00K
Net Income	-$23.46M	-$37.25M	-$33.13M	-$102.20M	-$22.39M
Diluted EPS	-2.77	-4.32	-3.82	-5.71	-1.24
Diluted Shares	8.47M	8.62M	8.67M	17.90M	24.71M

KPTI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$38.78M	$38.73M	$37.67M	$60.54M	$90.85M
Receivables	$35.24M	$32.93M	$31.88M	$26.18M	$23.36M
Inventory	$4.77M	$4.99M	$3.97M	$4.04M	$3.60M
Current Assets	$120.24M	$97.87M	$89.75M	$103.15M	$126.33M
Total Assets	$127.71M	$104.88M	$96.23M	$108.42M	$131.42M
Current Liabilities	$90.37M	$99.22M	$87.16M	$92.06M	$117.30M
Long-Term Debt	$154.83M	$152.25M	$176.74M	$205.88M	$192.16M
Total Debt	$186.70M	$190.62M	$196.42M	$233.61M	$230.87M
Total Liabilities	$333.60M	$343.81M	$365.49M	$401.34M	$397.06M
Retained Earnings	-$1.59B	-$1.62B	-$1.66B	-$1.76B	-$1.78B
Shareholders' Equity	-$205.88M	-$238.93M	-$269.26M	-$292.93M	-$265.65M
Working Capital	$29.87M	-$1.35M	$2.59M	$11.09M	$9.03M
Net Debt	$140.51M	$144.26M	$151.82M	$166.35M	$133.54M

KPTI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$38.98M	-$18.70M	-$5.86M	-$11.83M	-$22.73M
Free Cash Flow	-$38.98M	-$18.70M	-$5.86M	-$11.83M	-$22.73M
Depreciation & Amortisation	$78.00K	$78.00K	$121.00K	$19.00K	$12.00K
Stock-Based Compensation	$3.56M	$3.78M	$2.80M	$3.90M	$3.01M
Investing Cash Flow	$15.29M	$18.29M	$4.80M	$5.00M	$3.20M
Financing Cash Flow	$0.00	$356.00K	$0.00	$29.69M	$49.80M
Net Change in Cash	-$23.70M	-$56.00K	-$1.05M	$22.86M	$30.27M

Market Snapshot

About

Karyopharm Therapeutics is an oncology-focused pharmaceutical company developing novel drugs using Selective Inhibitor of Nuclear Export (SINE) technology. The company's lead product, selinexor, is approved for multiple cancer indications including multiple myeloma and diffuse large B-cell lymphoma. Karyopharm is advancing additional SINE compounds through clinical development for various hematologic and solid tumor malignancies.